To date only small animal models have been employed to assess the effect of mesenchymal stromal cell (MSC) therapy on acute pancreatitis (AP), the most common cause of hospitalization for gastrointestinal diseases worldwide. We outline the challenges inherent in the small animal models of AP. We also point to specific benefits afforded by the adoption of larger animal models. The potential for MSC therapeutics in the treatment of AP was recognized over a decade ago. With sharper focus on the form of AP and development of new MSC delivery routes in larger animals, we believe the challenge can be engaged.
Keywords: Acute pancreatitis; Autoimmune pancreatitis; Delivery route; Immune modulation; Large animal models; Mesenchymal stromal cells; Small animal models; Taurocholic acid.
Copyright © 2019 Elsevier Inc. All rights reserved.